Skip to Content

ChondroCelect

Active Substance: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Common Name: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
ATC Code: M09AX02
Marketing Authorisation Holder: TiGenix N.V.
Active Substance: characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Status: Authorised
Authorisation Date: 2009-10-05
Therapeutic Area: Cartilage Diseases
Pharmacotherapeutic Group: Other drugs for disorders of the musculo-skeletal system

Therapeutic Indication

Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.

Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².

The marketing authorisation for Chondrocelect has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide